Public Citizens urges FDA not to approve blood substitute

In a recent press release, Public Citizen explained its serious and troublesome objections to the blood substitute HBOC-201. Leading its opposition, Public Citizen stated that clinic data showed large increases in risk associated with the blood substitute, compared with either blood or standard non-blood IV fluids. Data demonstrated increases in death, serious cardiovascular events, and other adverse events in using HBOC-201 over non-blood IV solutions.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers